Aldeyra Therapeutics（ALDX）株式概要バイオテクノロジー企業であるアルデイラ・セラピューティクス社は、免疫疾患を治療するための治療法を発見・開発している。 詳細ALDX ファンダメンタル分析スノーフレーク・スコア評価3/6将来の成長5/6過去の実績0/6財務の健全性4/6配当金0/6報酬当社が推定した公正価値より47.3%で取引されている 収益は年間60.55%増加すると予測されています 過去5年間の収益は年間3.4%増加しました。 リスク分析US市場と比較して、過去 3 か月間の株価の変動が非常に大きい収益が 100 万ドル未満 ( $0 )意味のある時価総額がありません ( $91M )すべてのリスクチェックを見るALDX Community Fair Values Create NarrativeSee what 21 others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$1.59該当なし内在価値ディスカウントEst. Revenue$PastFuture-62m72016201920222025202620282031Revenue US$7.2Earnings US$1.2AdvancedSet Fair ValueView all narrativesGANXFeaturedThe Market Is Sleeping on This Parkinson's Biotech - And I Think That's a MistakeGain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.View narrativeLOLou_BaseneseCommunity ContributorUS$7.6FV • 75.3% 割安 内在価値ディスカウント5022.2%Revenue growth p.a.Set Fair Value3.7k2325429d agoAldeyra Therapeutics, Inc. 競合他社Q32 BioSymbol: NasdaqCM:QTTBMarket cap: US$81.9mForum MarketsSymbol: NasdaqCM:FRMMMarket cap: US$111.1mInovio PharmaceuticalsSymbol: NasdaqCM:INOMarket cap: US$91.8mCoya TherapeuticsSymbol: NasdaqCM:COYAMarket cap: US$99.2m価格と性能株価の高値、安値、推移の概要Aldeyra Therapeutics過去の株価現在の株価US$1.5952週高値US$6.1852週安値US$1.07ベータ1.331ヶ月の変化-5.36%3ヶ月変化-70.34%1年変化-43.42%3年間の変化-84.96%5年間の変化-87.26%IPOからの変化-77.92%最新ニュースAldeyra Therapeutics, Inc., Annual General Meeting, Jun 09, 2026Apr 28Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Aldeyra Therapeutics, Inc InvestorsMar 31Consensus revenue estimates fall by 63% Mar 19Price target decreased by 21% to US$7.50 Mar 18New minor risk - Market cap size Mar 18Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye DiseaseMar 17最新情報をもっと見るRecent updatesAldeyra Therapeutics, Inc., Annual General Meeting, Jun 09, 2026Apr 28Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Aldeyra Therapeutics, Inc InvestorsMar 31Consensus revenue estimates fall by 63% Mar 19Price target decreased by 21% to US$7.50 Mar 18New minor risk - Market cap size Mar 18Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye DiseaseMar 17Forecast breakeven date pushed back to 2027 Mar 05Consensus EPS estimates fall by 33% Jan 29Aldeyra Therapeutics, Inc. Announces Resignation of Stephen G. Machatha, Ph.D. as Chief Development Officer, Effective on or Before March 31, 2026Jan 01New minor risk - Share price stability Dec 16Aldeyra Therapeutics, Inc. Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye DiseaseDec 16Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet?Nov 27Forecast breakeven date pushed back to 2026 Nov 20Aldeyra Therapeutics, Inc. Announces Expansion of RASP Platform to Include Central Nervous System DiseasesNov 13No longer forecast to breakeven Nov 06Aldeyra Therapeutics, Inc. Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses Rasp Product Candidate Pipeline on Next-Generation MoleculesOct 28Consensus EPS estimates fall by 48% Oct 09Aldeyra Therapeutics, Inc. Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, Including Primary Vitreoretinal LymphomaAug 28Aldeyra Therapeutics, Inc. Receives Fast Track Designation for ADX-2191 for the Treatment of Retinitis PigmentosaAug 19Chief Development Officer recently sold US$114k worth of stock Aug 15Consensus EPS estimates upgraded to US$0.32 loss Aug 14Price target increased by 9.6% to US$9.50 Aug 11Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye DiseaseJul 17Aldeyra Therapeutics, Inc. Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for Adx-2191 for the Treatment of Primary Vitreoretinal LymphomaJun 26Consensus EPS estimates upgraded to US$0.53 loss Jun 20Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye DiseaseJun 18Consensus revenue estimates fall by 87% May 21New minor risk - Profitability May 15Aldeyra Therapeutics, Inc. Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA ResubmissionMay 06Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 10, 2025Apr 28Aldeyra Therapeutics Appoints Chip Clark to Board of DirectorsApr 17Price target decreased by 14% to US$8.57 Apr 04Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye DiseaseApr 03Forecast breakeven date moved forward to 2025 Mar 31Aldeyra Therapeutics Is Severely Undervalued Before PDUFA Mar 05New minor risk - Share price stability Mar 03Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?Feb 06New minor risk - Profitability Nov 14Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye DiseaseOct 03Chief Development Officer recently sold US$76k worth of stock Aug 15Chief Development Officer notifies of intention to sell stock Aug 14Price target increased by 8.1% to US$10.00 Aug 12New minor risk - Share price stability Aug 08Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of ReproxalapAug 08Consensus EPS estimates fall by 209% Aug 08New minor risk - Profitability Aug 05No longer forecast to breakeven Aug 05Aldeyra Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.Aug 02Is Aldeyra Therapeutics (NASDAQ:ALDX) Using Too Much Debt?Jun 21Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor RoundtableJun 20Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye DiseaseJun 15Consensus EPS estimates upgraded to US$0.18 loss May 23Forecast to breakeven in 2026 May 22Consensus EPS estimates fall by 163% May 12Aldeyra Therapeutics, Inc. Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye DiseaseMay 09No longer forecast to breakeven May 06New minor risk - Profitability May 05Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 04, 2024Apr 23New minor risk - Profitability Apr 03No longer forecast to breakeven Apr 03Forecast to breakeven in 2024 Mar 29New minor risk - Profitability Mar 28Aldeyra Therapeutics, Inc. Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye DiseaseMar 28CEO, President & Director recently sold US$581k worth of stock Mar 14CEO, President & Director notifies of intention to sell stock Mar 13Forecast to breakeven in 2024 Mar 11New minor risk - Profitability Mar 10Forecast to breakeven in 2024 Mar 08Is Aldeyra Therapeutics (NASDAQ:ALDX) Weighed On By Its Debt Load?Feb 16Consensus revenue estimates increase by 55% Jan 30Consensus revenue estimates increase by 57% Jan 05Aldeyra Therapeutics, Inc. Announces Positive Top-Line Results from A Phase 2 Clinical Trial of ADX-629 in Patients with Atopic DermatitisDec 19Consensus revenue estimates increase by 600% Dec 06New minor risk - Profitability Nov 29Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye DiseaseNov 29Consensus revenue estimates decrease by 82%, EPS upgraded Nov 10Health Check: How Prudently Does Aldeyra Therapeutics (NASDAQ:ALDX) Use Debt?Nov 06New minor risk - Market cap size Oct 19New minor risk - Profitability Oct 18Aldeyra Therapeutics, Inc. Announces Update of U.S. Food and Drug Administration Relating to the New Drug Application for Reproxalap for the Treatment of the Signs and Symptoms of Dry Eye DiseaseOct 17Consensus revenue estimates decrease by 61%, EPS upgraded Oct 17Price target decreased by 13% to US$17.86 Oct 16CEO, President & Director exercised options and sold US$492k worth of stock Sep 13Frank R. Cruz Announces Securities Fraud Lawsuit Against Aldeyra Therapeutics, IncSep 03Consensus revenue estimates increase by 36% Aug 22Consensus revenue estimates decrease by 73%, EPS upgraded Aug 10Holzer & Holzer, LLC Files Class Action Lawsuit Against Aldeyra Therapeutics, IncAug 02Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX--629 in Patients with Chronic CoughJun 28Consensus revenue estimates increase by 15% Jun 22Aldeyra Therapeutics, Inc. Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE--2 Trial of Reproxalap in Allergic ConjunctivitisJun 16Aldeyra Therapeutics, Inc., Annual General Meeting, Jun 30, 2023May 25Aldeyra Therapeutics (NASDAQ:ALDX) Has Debt But No Earnings; Should You Worry?Mar 26Consensus revenue estimates decrease by 41%, EPS upgraded Mar 16Price target increased by 8.4% to US$21.83 Mar 12Aldeyra Therapeutics, Inc. Advances Investigational Oral RASP Modulator ADX--629 Into New Phase 2 Systemic Disease TrialsFeb 18Aldeyra Therapeutics, Inc. Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye DiseaseFeb 08Forecast to breakeven in 2025 Feb 02Insufficient new directors Feb 01株主還元ALDXUS BiotechsUS 市場7D2.6%-2.5%0.8%1Y-43.4%26.8%27.7%株主還元を見る業界別リターン: ALDX過去 1 年間で26.8 % の収益を上げたUS Biotechs業界を下回りました。リターン対市場: ALDXは、過去 1 年間で27.7 % のリターンを上げたUS市場を下回りました。価格変動Is ALDX's price volatile compared to industry and market?ALDX volatilityALDX Average Weekly Movement25.2%Biotechs Industry Average Movement10.8%Market Average Movement7.2%10% most volatile stocks in US Market16.2%10% least volatile stocks in US Market3.3%安定した株価: ALDXの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: ALDXの 週次ボラティリティ は、過去 1 年間で16%から25%に増加しました。会社概要設立従業員CEO（最高経営責任者ウェブサイト20048Todd Bradywww.aldeyra.comバイオテクノロジー企業であるアルデイラ・セラピューティクス社は、免疫介在性疾患の治療を目的とした治療法の発見と開発を行っている。同社の主要製品候補は、反応性アルデヒド種（RASP）モジュレーターであるreproxalapで、ドライアイとアレルギー性結膜炎の治療薬として第III相臨床試験中であり、ジヒドロ葉酸還元酵素阻害剤であるADX-2191は原発性網膜硝子体リンパ腫と網膜色素変性症の治療薬である。また、経口投与のRASPモジュレーターであるADX-629も開発しており、COVID-19、アトピー性喘息、乾癬、アルコール中毒の治療薬として第2相臨床試験中である。さらに、ADX 248、ADX 246、その他の新規RASPモジュレーターを含む前臨床RASPプラットフォームを開発し、RASPに関連する様々な疾患の治療に取り組んでいる。同社は以前はAldexa Therapeutics, Inc.として知られていたが、2014年3月にAldeyra Therapeutics, Inc.に社名を変更した。Aldeyra Therapeutics, Inc.は2004年に法人化され、マサチューセッツ州レキシントンを拠点としている。もっと見るAldeyra Therapeutics, Inc. 基礎のまとめAldeyra Therapeutics の収益と売上を時価総額と比較するとどうか。ALDX 基礎統計学時価総額US$91.48m収益（TTM）-US$33.85m売上高(TTM)n/a0.0xP/Sレシオ-2.8xPER（株価収益率ALDX は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計ALDX 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用US$33.85m収益-US$33.85m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.56グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率34.5%ALDX の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/01 04:44終値2026/05/01 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Aldeyra Therapeutics, Inc. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。17 アナリスト機関Keay NakaeAscendiant Capital Markets LLCEsther Lannie HongBerenbergDouglas BuchananBrean Capital Historical (Janney Montgomery)14 その他のアナリストを表示
GANXFeaturedThe Market Is Sleeping on This Parkinson's Biotech - And I Think That's a MistakeGain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.View narrativeLOLou_BaseneseCommunity ContributorUS$7.6FV • 75.3% 割安 内在価値ディスカウント5022.2%Revenue growth p.a.Set Fair Value3.7k2325429d ago
Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Aldeyra Therapeutics, Inc InvestorsMar 31
Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye DiseaseMar 17
Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Aldeyra Therapeutics, Inc InvestorsMar 31
Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye DiseaseMar 17
Aldeyra Therapeutics, Inc. Announces Resignation of Stephen G. Machatha, Ph.D. as Chief Development Officer, Effective on or Before March 31, 2026Jan 01
Aldeyra Therapeutics, Inc. Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye DiseaseDec 16
Aldeyra Therapeutics, Inc. Announces Expansion of RASP Platform to Include Central Nervous System DiseasesNov 13
Aldeyra Therapeutics, Inc. Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses Rasp Product Candidate Pipeline on Next-Generation MoleculesOct 28
Aldeyra Therapeutics, Inc. Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, Including Primary Vitreoretinal LymphomaAug 28
Aldeyra Therapeutics, Inc. Receives Fast Track Designation for ADX-2191 for the Treatment of Retinitis PigmentosaAug 19
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye DiseaseJul 17
Aldeyra Therapeutics, Inc. Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for Adx-2191 for the Treatment of Primary Vitreoretinal LymphomaJun 26
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye DiseaseJun 18
Aldeyra Therapeutics, Inc. Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA ResubmissionMay 06
Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye DiseaseApr 03
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye DiseaseOct 03
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of ReproxalapAug 08
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor RoundtableJun 20
Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye DiseaseJun 15
Aldeyra Therapeutics, Inc. Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye DiseaseMay 09
Aldeyra Therapeutics, Inc. Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye DiseaseMar 28
Aldeyra Therapeutics, Inc. Announces Positive Top-Line Results from A Phase 2 Clinical Trial of ADX-629 in Patients with Atopic DermatitisDec 19
Aldeyra Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye DiseaseNov 29
Aldeyra Therapeutics, Inc. Announces Update of U.S. Food and Drug Administration Relating to the New Drug Application for Reproxalap for the Treatment of the Signs and Symptoms of Dry Eye DiseaseOct 17
Aldeyra Therapeutics Announces Statistically Significant Reduction in Cough Frequency in Phase 2 Clinical Trial of ADX--629 in Patients with Chronic CoughJun 28
Aldeyra Therapeutics, Inc. Announces Achievement of Statistical Significance for Primary Endpoint and All Secondary Endpoints in Phase 3 INVIGORATE--2 Trial of Reproxalap in Allergic ConjunctivitisJun 16
Aldeyra Therapeutics, Inc. Advances Investigational Oral RASP Modulator ADX--629 Into New Phase 2 Systemic Disease TrialsFeb 18
Aldeyra Therapeutics, Inc. Announces FDA Acceptance of New Drug Application for Reproxalap for the Treatment of Dry Eye DiseaseFeb 08
